AAAmir Parsa Abhari

Amir Parsa Abhari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Parsa Abhari has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammad Fakhrolmobasheri

    Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

    3 shared publications
  • Davood Shafie

    Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

    2 shared publications
  • Sadegh Mazaheri-Tehrani

    Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

    2 shared publications
  • Amir Mohamad Msc Mozafari

    Clinical Research Development Unit, kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran

    1 shared publication
  • Amirhossein Ebrahimi

    Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

    1 shared publication
  • Arman Shekarian

    Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    1 shared publication

Latest Publications

  • Sodium-Glucose Cotransporter 2 Inhibitors and Pulmonary Hypertension: A Systematic Review

    by Farzad Adelparvar, Mohammad Fakhrolmobasheri, Fatemeh Qorbani, Davood Shafie, Maryam Heidarpour, Maryam Nasr, Amir Mohamad Msc Mozafari, Amir Parsa Abhari

    Pulmonary hypertension (PH) is a chronic disease characterized by elevated pulmonary arterial pressure, often leading to right ventricular failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are potential therapies for PH due to their cardiovascular effects. In this systematic review, we aim to assess the safety and efficacy of SGLT2 inhibitors in improving pulmonary hemodynamics and cardiac parameters in patients with PH. A systematic review search until November 2024 was conducted across 8 databases. Six studies involving 462 participants were included, comprising 3 randomized controlled trials, 2 observational studies, and 1 cohort study. SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, significantly reduced pulmonary arterial pressure in most studies. Cardiac indices, such as left ventricular diastolic and systolic diameters, E/e’, and left ventricular ejection fraction, also improved. However, one randomized controlled trial reported no significant improvement in the hemodynamic outcomes. SGLT2 inhibitors are assumed to be promising in the management of PH through cardiac and hemodynamic improvements. Further research is needed to elucidate their efficacy and the underlying mechanisms.


  • Open Access

    The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis

    by Reza Amani-Beni, Bahar Darouei, Davood Shafie, Mohammadreza Mortaheb, Mohammadreza Malakoutikhah, Amirhossein Ebrahimi, Sara Heidari-Hasanabadi, Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Sadegh Mazaheri-Tehrani, et al.

    Managing electrolyte abnormalities, particularly sodium and potassium, in patients with heart failure (HF) remains a concern. A novel anti-diabetic drug, sodium-glucose co-transporter-2 (SGLT2) inhibitors, has become suitable for HF patients, improving cardiovascular outcomes. Therefore, we aimed to conduct a meta-analysis to evaluate the effect of SGLT2 inhibitors on serum sodium and potassium. We systematically searched five databases, identifying randomized clinical trials (RCTs) reporting changes in serum sodium and potassium levels with SGLT2 inhibitors compared to comparator groups. Outcomes were presented as weighted mean differences (WMD) and standardized MD (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were also conducted. 13 studies were included, with 13 studies with 10,617 participants reporting on serum sodium and nine studies with 9877 participants on serum potassium. In acute HF, SGLT2 inhibitors did not significantly affect serum sodium (WMD: 1.21 mmol/L; 95% CI: − 0.79, 3.21) or potassium levels (WMD: 0.11 mEq/L; 95% CI: − 0.20, 0.42). Subgroup analyses suggested possible variations by follow-up duration (< 7 days vs. ≥ 30 days) and drug type, but findings remained non-significant. Sensitivity analysis using the leave-one-out method and risk of bias assessment results showed no considerable changes in the statistical significance of the pooled results. Similarly, in chronic HF, no significant differences were observed for serum sodium (WMD: 0.23 mmol/L; 95% CI: − 0.45, 0.91) or potassium (WMD: 0.07 mEq/L; 95% CI: − 0.29, 0.44). Sensitivity and subgroup analyses based on duration, drug type, diabetes status, renal function, or systolic blood pressure did not reveal clinically meaningful differences across all analyses. For all analyses, Egger’s test was non-significant, indicating no strong evidence of small‐study effects. Moreover, the trim-and-fill method combined with the funnel plot did not identify any missing studies, and the recalculated effect size remained unchanged. SGLT2 inhibitors did not significantly alter serum sodium or potassium levels in acute or chronic HF, suggesting that these drugs can be safe regarding electrolyte disturbances. Additional RCTs are warranted to enhance the robustness of evidence regarding the mechanisms and effects of SGLT2 inhibitors on serum electrolyte levels, considering variations across different types of SGLT2 inhibitors.


  • Open Access

    In Patients Presenting with an ST-Elevation Myocardial Infarction, Overweight and Obese Patients Have the Lowest Inpatient Mortality whereas Cachexia Patients Have the Highest Inpatient Mortality Followed by Patients with Morbid Obesity

    by Mohammad Reza Movahed, Amir Parsa Abhari, Mehrtash Hashemzadeh

    Introduction: The obesity paradox has been observed in patients with cardiovascular disease. The goal of this study was to evaluate whether obesity has a protective effect in patients presenting with an ST elevation myocardial infarction (STEMI). Method: Using the large Nationwide Inpatient (NIS) sample database, we evaluated the mortality in patients with a STEMI based on weight categories. Results: A total of 2,161,640 STEMI patients were found in the database over age 18. We found that overweight and obesity had the lowest mortality using univariate (overweight mortality of 5% vs. obesity mortality of 6.5% vs. 10.9% for normal weights) and multivariate analyses (overweight OR: 0.52, CI: 0.43–063; p < 0.001 and obesity OR: 0.7, CI: 0.67–0.74; p < 0.001), whereas cachexia was associated with the highest mortality in the univariate (cachexia 24.5%) and multivariate (OR: 2.28, CI: 2.13–2.44; p < 0.001) analyses, followed by morbid obesity in the multivariate analysis (OR: 1.07, CI: 1.02–1.12; p = 0.004). Conclusions: We observed a partial obesity paradox in patients with a STEMI showing that overweight have the best survival rates followed by obesity. Cachexia followed by morbid obesity had the lowest survival rates.


  • Open Access

    Serum Selenium Levels and Lipid Profile: A Systematic Review and Meta-analysis of Observational Studies

    by Sadegh Mazaheri-Tehrani, Amir Parsa Abhari, Negar Ostadsharif, Arman Shekarian, Mahshad Vali, Elahe Saffari, Kasra Talebi Anaraki, Mohammad Ali Haghighatpanah, Mohammad Fakhrolmobasheri, Marek Kieliszek

    Selenium is a trace element with pivotal roles in metabolic processes. Studies suggested that selenium deficiency could lead to impaired lipid profiles. However, inconsistent results have been reported regarding the association between serum selenium concentrations and lipid profile (triglycerides, LDL, HDL, VLDL, and total cholesterol). Thus, we aimed to review the correlation between them. A systematic literature search was conducted in PubMed, Embase, Web of Science, Scopus, and Google Scholar until 31 December 2023. The relevant correlation coefficients were used as desired effect sizes to assess the correlation between selenium level and lipid profile. Among 8291 records found in the primary search, 47 and 34 articles were included in the systematic review and meta-analysis, respectively. All included studies were observational investigations and had acceptable quality. Our results failed to reach strong evidence supporting the correlation between serum selenium level and lipid profiles, except for HDL, which showed a weak correlation among both adults (r = 0.1 [0.03:0.17]; I 2 = 71%) and pediatrics (r = 0.08 [0.03:0.14]; I 2 = 38%). Subgroup analyses based on gender did not reveal a significant or strong correlation with selenium levels (except for total cholesterol in males (r = 0.12 [0.01:0.22]; I 2 = 52%)). The results did not change after the sensitivity analysis. Although some previous studies have suggested that selenium deficiency could lead to impaired lipid profile, the findings of this study indicate no strong correlation between serum selenium levels and lipid profile.


  • Comparison of Combined Guidance of Fluoroscopy and Ultrasonography in Total Tubeless Percutaneous Nephrolithotomy with the Standard Method: A Randomized Clinical Trial

    by Seyed Reza Hosseini, Maryam Gholamnejad, Mohammad Ghassem Mohseni, Amir Parsa Abhari, Seyed Mohammad Kazem Aghamir

    Objective: Utilizing the combination of fluoroscopy and ultrasonography during Percutaneous Nephrolithotomy (PCNL) to minimize radiation exposure. Methods: In this randomized clinical trial, 118 patients with urinary stones who were candidates for PCNL surgery in the prone position were selected and divided into two groups (with an allocation ratio of 1:1). Cases were grouped according to whether ultrasonography was used for renal tract dilation and Amplatz sheath placement. The number of attempts to establish proper renal access, the time interval between access to the targeted calyx and nephroscope entrance, and the Clavien-Dindo score were collected. Results: The mean age of all patients was 46.12 +/- 11.28 (45.6 +/- 11.2 in the total fluoroscopy group and 46.5 +/- 11.4 in the combined group) years (20-66). The intergroup differences in the baseline features were not significant. The mean duration of fluoroscopy time was significantly reduced in the combined guidance group (36.22 +/- 10.73 vs. 23.05 +/- 8.94 seconds, ( P -value = 0.001). Moreover, the difference in the distribution of Amplatz location on the nephroscopy time was meaningful ( P -value = 0.016). However, intergroup differences in the number of attempts to successful puncture, length of hospitalization, recovery time, and postoperative complications, including gross hematuria duration, blood loss volume, pack cells requirement, pain score immediately and 6 hours after the surgery, and Clavien-Dindo score were not meaningful. Conclusion: It can be concluded that the use of ultrasound with X-ray in prone PCNL compared to the use of X-rays alone can significantly reduce the duration of radiation without increasing the risk of intra-operative and postoperative detrimental events.


  • Relative Values of Hematological Indices for Prognosis of Heart Failure: A Mini-Review

    by Davood Shafie, Amir Parsa Abhari, Mohammad Fakhrolmobasheri

    Owing to the augmented perception of heart failure (HF) pathophysiology, management of the affected patients has been improved dramatically; as with the identification of the inflammatory background of HF, new avenues of HF prognosis research have been opened up. In this regard, relative values of hematologic indices were demonstrated by a growing body of evidence to successfully predict HF outcomes. Cost-effectiveness, accessibility, and easy obtainability of these relative values make them a precious option for the determination of HF prognosis; particularly in low-income developing countries. In this short review, we aimed to present the current literature on the predictability of these hematologic parameters for HF outcomes.


  • Open Access

    Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis

    by Masoud Etemadifar, Fatemeh Sabeti, Amir Parsa Abhari, Fatemeh Etemadifar, Mehri Salari

    Background Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the central nervous system. Due to their many shared presentations, NMOSD misdiagnosis as MS is a rather common medical misconduct. Few studies have focused on the reasons for these misdiagnoses and how they were corrected in the end. Methods In this study, we report 10 cases of long-term NMOSD misdiagnosis as MS. We reviewed patients' medical records and collected their clinical, radiographic and laboratory data. Also, reasons for the misdiagnoses and how NMOSD diagnosis was confirmed were investigated. Results Nine patients (90%) were female and one was male (10%) with a mean age of 42.88 ± 7.09. Mean EDSS at onset was 1.44 ± 0.39 and 6 patients (60%) were NMO-IgG positive. All brain MRIs at onset had periventricular lesions which fulfilled MS diagnosis. However, periventricular lesions were reduced in 5 patients by the time of NMOSD diagnosis and no longer fulfilled MS diagnostic criteria. Only 2 patients had spinal lesions at onset one of which was a long extending transverse myelitis (LETM). Moreover, new LETM lesions were observed in the spinal MRI of 7 patients at the time of NMOSD diagnosis which led to the diagnosis; either alone or along with the confirmation of autoantibody seropositivity. In 3 patients, NMO-IgG seropositivity in the absence of LETM, led to NMOSD confirmation. Conclusion In order to further avoid misdiagnoses, we suggest to carefully follow the patients with uncertain diagnoses and check several times for NMO-IgG and other autoantibodies reported in NMOSD.

  • Open Access

    Epidemiological and clinical features of pediatric-onset multiple sclerosis: A population-based study in Isfahan, Iran, between 1997-2020

    by Masoud Etemadifar, Amir Parsa Abhari, Ghasem Yadegarfar, Mehri Salari, Mohammadreza Ghazavi, Milad Rayani, Hosein Nouri, Parisa Kargaran, Shahrbanoo Mazaheri, Homa Saadat

    Background: Pediatric-onset multiple sclerosis (POMS) is an autoimmune demyelinating disorder of the central nervous system (CNS), affecting individuals younger than 18 years of age. We sought to characterize the epidemiological and clinical features of patients with POMS in Isfahan, Iran, from April 1997 to March 2020. Methods: The medical records of patients with POMS in the databases of Isfahan Department of Public Health and Isfahan Multiple Sclerosis Society (IMSS) were retrospectively reviewed. The 2006 and 2016 Isfahan Province population censuses were used as reference values for assessing the temporal trend of POMS. Results: From April 1997 to March 2020, 509 individuals under18 years of age were diagnosed with POMS in Isfahan. 404 of these patients (79.4%) were girls, and 105 patients (20.6%) were boys (a female to male ratio of 3.85:1). Most of the patients (83%) were monosymptomatic at onset, with optic neuritis and brainstem-cerebellar disorders being the most frequent initial presentations. Mean ± standard deviation (SD) of age at disease diagnosis was 15.8 ± 2.5 years (ranging from 3 to 18, mode = 18).From April 2019 to March 2020, the crude prevalence and the crude incidence rate of the POMS were 5.42 per 100000 and 1.86 per 100000, respectively. Poisson regression analysis revealed a 3.4% increase in the incidence rate of POMS from April 1997 to March 2020 [relative rate:1.034, 95% confidence interval (CI): 1.021-1.048]. Conclusion: The female to male ratio in our cohort was significantly higher than any other studies conducted previously. The high female to male ratio and increasing incidence of the disease suggest increasing regionalization of care.